Cell-derived biomimetic drug delivery system for inflammatory bowel disease therapy
Source abstract
Abstract
Inflammatory bowel disease (IBD) is a chronic recurrent disease with an increasing incidence year by year. At present, no safe and effective treatment for IBD exists. Thus, there is an urgent need to create new therapeutic options that have decreased adverse effects and positive clinical efficacy. A range of nanomaterials have fueled the advancement of nanomedicine in recent years, which is establishing more appealing and prospective treatment approaches for IBD. However, traditional synthetic nanomaterials still have some problems in the IBD drug delivery process, such as weak targeting ability of vectors, difficulty escaping immune surveillance, and poor biosecurity. Natural sources of biological nanomaterials have been identified to solve the above problems. A drug delivery system based on bionic technology is expected to achieve a new breakthrough in the targeted therapy of IBD by nanotechnology due to its organic integration of low immunogenicity and natural targeting of biological materials and the controllability and versatility of synthetic nanocarrier design. We begin this review by outlining the fundamental traits of both inflammatory and healthy intestinal microenvironments. Subsequently, we review the latest application of a cell-derived bionic drug delivery system in IBD therapy. Finally, we discuss the development prospects of this delivery system and challenges to its clinical translation. Biomimetic nanotherapy is believed to offer a new strategy for the treatment of IBD.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Phagocytosis and Immune Regulation · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cell membrane and bioactive factors derived from mesenchymal stromal cells: cell-free based therapy for inflammatory bowel diseases10.4252/wjsc.v11.i9.618 ↗
2. Targeting improves MSC treatment of inflammatory bowel disease10.1038/mt.2010.54 ↗
3. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities10.1097/01.MIB.0000195385.19268.68 ↗
4. Newer biologic and small-molecule therapies for inflammatory bowel disease10.1056/NEJMra1907607 ↗
5. ‘Green’ nanotherapeutics from tea leaves for orally targeted prevention and alleviation of colon diseases10.1016/j.biomaterials.2021.121178 ↗
6. Advanced nanomedicine: redefining therapeutic paradigms for inflammatory bowel disease
7. Nanotherapeutics in the treatment of acute respiratory distress syndrome10.1016/j.lfs.2021.119428 ↗
8. Recent progress in therapeutic strategies and biomimetic nanomedicines for rheumatoid arthritis treatment10.1080/17425247.2022.2094364 ↗
9. Red blood cells: the metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers10.1016/j.addr.2021.113992 ↗
10. Cell membrane nanomaterials composed of phospholipids and glycoproteins for drug delivery in inflammatory bowel disease: a review10.1016/j.ijbiomac.2023.126000 ↗
11. Oral delivery of layer-by-layer coated exosomes for colitis therapy10.1016/j.jconrel.2023.01.017 ↗
12. Advances in the treatment of inflammatory bowel disease: focus on polysaccharide nanoparticulate drug delivery systems10.1016/j.addr.2021.114101 ↗
13. Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review10.1039/D3BM01645E ↗
14. Intestinal mucosal barrier is regulated by intestinal tract neuro-immune interplay10.3389/fphar.2021.659716 ↗
15. Inflammatory bowel diseases (IBD) and the microbiome—searching the crime scene for clues10.1053/j.gastro.2020.09.056 ↗
16. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease10.3390/nu14235140 ↗
17. GATA6 deficiency leads to epithelial barrier dysfunction and enhances susceptibility to gut inflammation10.1093/ecco-jcc/jjab145 ↗
18. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation10.1136/gutjnl-2012-303955 ↗
19. FOXO1 orchestrates the intestinal homeostasis via neuronal signaling in group 3 innate lymphoid cells10.1084/jem.20230133 ↗
20. The gut-brain Axis in inflammatory bowel disease—current and future perspectives10.3390/ijms22168870 ↗
21. Lipid Rafts as a membrane-Organizing principle10.1126/science.1174621 ↗
22. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions10.1038/nnano.2012.212 ↗
23. Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery10.1039/C9BM01392J ↗
24. Unveiling the in vivo protein corona of circulating leukocyte-like carriers10.1021/acsnano.7b00376 ↗
25. A biomimetic nanoplatform with improved inflammatory targeting behavior for ROS scavenging‐based treatment of ulcerative colitis10.1002/adhm.202370181 ↗
26. “Platelet-coated bullets” biomimetic nanoparticles to ameliorate experimental colitis by targeting endothelial cells10.1016/j.bioadv.2023.213378 ↗
27. Cell membrane‐coated nanoparticles for the treatment of bacterial infection10.1002/wnan.1825 ↗
28. Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease10.1016/j.jare.2021.07.002 ↗
29. Recent advances in biomimetic nanodelivery systems: new brain-targeting strategies10.1016/j.jconrel.2023.05.009 ↗
30. Bioinspired and biomimetic strategies for inflammatory bowel disease therapy10.1039/D3TB02995F ↗
31. Therapeutic potential of exosome‐based personalized delivery platform in chronic inflammatory diseases
32. Garlic-derived exosome-like nanovesicles alleviate dextran sulphate sodium-induced mouse colitis via the TLR4/MyD88/NF-κB pathway and gut microbiota modulation10.1039/D3FO01094E ↗
33. Oral TNF-α siRNA delivery via milk-derived exosomes for effective treatment of inflammatory bowel disease
34. Exosome cargo in milk as a potential marker of cow health10.1017/S0022029920000485 ↗
35. Advanced generation therapeutics: biomimetic nanodelivery system for tumor immunotherapy10.1021/acsnano.3c10212 ↗
36. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment10.1016/j.jconrel.2022.02.028 ↗
37. Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine10.7150/thno.48448 ↗
38. Macrophage-biomimetic nanoparticles ameliorate ulcerative colitis through reducing inflammatory factors expression10.1159/000519363 ↗
39. Immuno‐engineered nanodecoys for the multi‐target anti‐inflammatory treatment of autoimmune diseases10.1002/adma.202108817 ↗
40. Capsulated cellular nanosponges for the treatment of experimental inflammatory bowel disease10.1021/acsnano.3c03959 ↗
41. Genome-editing prodrug: targeted delivery and conditional stabilization of CRISPR-Cas9 for precision therapy of inflammatory disease10.1126/sciadv.abj0624 ↗
42. ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease10.1016/j.actbio.2023.02.026 ↗
43. Biomimetic MOF nanoparticles delivery of C-Dot Nanozyme and CRISPR/Cas9 system for site-specific treatment of ulcerative colitis10.1021/acsami.1c21700 ↗
44. Ulcerative colitis-specific delivery of keratinocyte growth factor by neutrophils-simulated liposomes facilitates the morphologic and functional recovery of the damaged colon through alleviating the inflammation10.1016/j.jconrel.2019.02.034 ↗
45. Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases10.1039/C7NR04734G ↗
46. Grapefruit-derived Nanovectors Use an activated leukocyte trafficking pathway to deliver therapeutic agents to inflammatory tumor sites10.1158/0008-5472.CAN-14-3095 ↗
47. Probiotic‐Inspired nanomedicine restores intestinal homeostasis in colitis by regulating redox balance, immune responses, and the gut microbiome
48. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines10.1038/s41467-020-16439-7 ↗
49. Recent advances of cell membrane-coated nanoparticles for therapy of bacterial infection
50. Biomimetic nanoparticles for inflammation targeting10.1016/j.apsb.2017.12.002 ↗
51. Cell membrane coating technology: a promising strategy for Biomedical applications10.1007/s40820-019-0330-9 ↗
52. Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles10.1021/acs.nanolett.8b03439 ↗
53. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management10.1073/pnas.1714267114 ↗
54. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease 1,2 1This article is part of a series of reviews on “Reactive Oxygen and Nitrogen in Inflammation.”
55. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice10.1053/j.gastro.2009.12.041 ↗
56. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo10.1073/pnas.2631433100 ↗
57. Neutrophils in cancer: neutral no more10.1038/nrc.2016.52 ↗
58. Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats10.1053/gast.1996.v110.pm8612996 ↗
59. Extracellular vesicles: the next generation theranostic nanomedicine for inflammatory bowel disease10.2147/IJN.S370784 ↗
60. M2 macrophage-derived exosomal miR-590-3p attenuates DSS-induced mucosal damage and promotes epithelial repair via the LATS1/YAP/β-catenin signalling Axis10.1093/ecco-jcc/jjaa214 ↗
61. Exosomes derived from M2b macrophages attenuate DSS-induced colitis10.3389/fimmu.2019.02346 ↗
62. Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis10.3109/00365521.2010.490596 ↗
63. Immunosuppressive exosomes from TGF-β1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells10.1038/cr.2011.196 ↗
64. Extracellular vesicles derived from bone marrow mesenchymal stem cells attenuate dextran sodium sulfate-induced ulcerative colitis by promoting M2 macrophage polarization10.1016/j.intimp.2019.04.020 ↗
65. Exosomes derived from human umbilical cord mesenchymal stem cells relieve inflammatory bowel disease in mice
66. Human adipose mesenchymal stem cell-derived exosomes protect mice from DSS-induced inflammatory bowel disease by promoting intestinal-stem-cell and epithelial regeneration10.14336/AD.2021.0601 ↗
67. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases10.3389/fimmu.2021.749192 ↗
68. Lactobacillus paracasei-derived extracellular vesicles attenuate the intestinal inflammatory response by augmenting the endoplasmic reticulum stress pathway10.1038/s12276-019-0359-3 ↗
69. Effect of extracelluar vesicles derived from Akkermansia muciniphila on intestinal barrier in colitis mice10.3390/nu15224722 ↗
70. Engineering fucoxanthin-loaded probiotics' membrane vesicles for the dietary intervention of colitis10.1016/j.biomaterials.2023.122107 ↗
71. Therapeutic effects of kefir grain Lactobacillus-derived extracellular vesicles in mice with 2,4,6-trinitrobenzene sulfonic acid-induced inflammatory bowel disease10.3168/jds.2018-15014 ↗
72. Bacteroides acidifaciens and its derived extracellular vesicles improve DSS-induced colitis10.3389/fmicb.2023.1304232 ↗
73. Clostridium butyricum and its derived extracellular vesicles modulate gut homeostasis and ameliorate acute experimental colitis10.1128/spectrum.01368-22 ↗
74. Lactobacillus rhamnosus GG derived extracellular vesicles modulate gut microbiota and attenuate inflammatory in DSS-induced colitis mice10.3390/nu13103319 ↗
75. Nanoprobiotics for remolding the pro-inflammatory microenvironment and microbiome in the treatment of colitis10.1021/acs.nanolett.3c02408 ↗
76. EpCAM-dependent extracellular vesicles from intestinal epithelial cells maintain intestinal tract immune balance10.1038/ncomms13045 ↗
77. Plant-derived exosomal MicroRNAs shape the gut microbiota10.1016/j.chom.2018.10.001 ↗
78. Amelioration of colitis progression by ginseng-derived exosome-like nanoparticles through suppression of inflammatory cytokines10.1016/j.jgr.2023.01.004 ↗
79. Targeting immune cell circuits and trafficking in inflammatory bowel disease10.1038/s41590-019-0415-0 ↗
80. The impact of immune cell-derived exosomes on immune response initiation and immune system function10.2174/1381612826666201207221819 ↗
81. M1 Macrophage exosomes MiR‐21a‐5p aggravates inflammatory bowel disease through decreasing E‐cadherin and subsequent ILC2 activation10.1111/jcmm.16348 ↗
82. Macrophage polarization10.1146/annurev-physiol-022516-034339 ↗
83. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages10.3389/fimmu.2015.00263 ↗
84. Quantitative biodistribution and pharmacokinetics study of GMP-grade exosomes labeled with 89Zr radioisotope in mice and rats10.3390/pharmaceutics14061118 ↗
85. Transforming growth factor-β1 and its receptors in patients with ulcerative colitis10.1016/j.intimp.2009.02.014 ↗
86. TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism10.1136/jitc-2020-001798 ↗
87. Regulation and function of extracellular matrix intestinal epithelial restitution in vitro10.1152/ajpgi.1996.271.5.G729 ↗
88. Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?10.1007/s00018-013-1290-8 ↗
89. Mesenchymal stem cell exosomes10.1016/j.semcdb.2015.03.001 ↗
90. Exosome-induced regulation in inflammatory bowel disease10.3389/fimmu.2019.01464 ↗
91. Exosomes in intestinal inflammation10.3389/fphar.2021.658505 ↗
92. Exosome‐mediated effects and applications in inflammatory bowel disease10.1111/brv.12608 ↗
93. Prevailing Knowledge on the bioavailability and biological activities of Sulphur compounds from Alliums: a potential drug candidate10.3390/molecules25184111 ↗
94. MicroRNAs in Breastmilk and the Lactating breast: potential immunoprotectors and developmental regulators for the infant and the mother10.3390/ijerph121113981 ↗
95. Exosome-derived MicroRNAs of human milk and their effects on infant health and development10.3390/biom11060851 ↗
96. Milk-derived exosomes and metabolic regulation10.1146/annurev-animal-020518-115300 ↗
97. Yeast cell-derived delivery systems for bioactives10.1016/j.tifs.2021.10.020 ↗
98. Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery10.1021/bc700329p ↗
99. Entrapment of macrophage-target nanoparticles by yeast microparticles for Rhein delivery in ulcerative colitis treatment10.1021/acs.biomac.1c00425 ↗
100. Robust reactive oxygen species modulator hitchhiking yeast microcapsules for colitis alleviation by trilogically intestinal microenvironment renovation